Follow-up data for self-efficacy and health status and between-group differences after adjusting for baseline values using analysis of covariance (results of intention-to-treat analyses)
| Control group (N=60) | Intervention group (N=68) | Mean difference | ||
|---|---|---|---|---|
| Domain—time point (range) | Mean (95% CI) | Mean (95% CI) | ENAT-usual care (95% CI) | T-statistic (p value) |
| ASES (score range; higher score=greater self-efficacy) | ||||
| ASES-Pain—week 16 (5–50) | 25.8 (23.8 to 27.8) | 27.7 (26.2 to 29.2) | 1.86 (−0.63 to 4.35) | 1.48 (0.142)* |
| ASES-Pain —week 32 (5–50) | 26.9 (25.2 to 28.5) | 31.2 (30.0 to 32.5) | 4.36 (1.17 to 7.55) | 2.72 (0.008) * |
| ASES-Other symptoms—week 16 (6–60) | 33.5 (31.6 to 35.5) | 35.8 (34.2 to 37.3) | 2.22 (−1.15 to 5.59) | 1.31 (0.194)* |
| ASES-Other symptoms—week 32 (6–60) | 34.0 (32.4 to 35.7) | 39.9 (38.6 to 41.1) | 5.84 (2.07 to 9.62) | 3.07 (0.003)* |
| AIMS2-SF (score range; zero=good health status) | ||||
| AIMS2-SF: physical—week 16 (0–10) | 3.01 (2.56 to 3.47) | 2.81 (2.47 to 3.15) | −0.21 (−0.72 to 0.30) | −0.83 (0.409) |
| AIMS2-SF: physical—week 32 (0–10) | 3.05 (2.56 to 3.53) | 2.84 (2.48 to 3.20) | −0.21 (−0.76 to 0.34) | −0.77 (0.442) |
| AIMS2-SF: symptoms—week 16 (0–10) | 4.77 (4.16 to 5.38) | 4.56 (4.09 to 5.03) | −0.21 (−0.93 to 0.52) | −0.57 (0.572) |
| AIMS2-SF: symptoms—week 32 (0–10) | 5.25 (4.76 to 5.74) | 4.21 (3.79 to 4.63) | −1.04 (−1.85 to −0.22) | −5.54 (0.013) |
| AIMS2-SF: affect—week 16 (0–10) | 4.00 (3.59 to 4.41) | 3.84 (3.44 to 4.24) | −0.15 (−0.58 to 0.27) | −0.71 (0.479) |
| AIMS2-SF: affect—week 32 (0–10) | 4.29 (3.94 to 4.64) | 3.44 (3.10 to 3.78) | −0.86 (−1.46 to −0.26) | −2.84 (0.006) |
| AIMS2-SF: social week 16 (0–10) | 5.60 (5.22 to 5.98) | 5.45 (5.09 to 5.81) | −0.15 (−0.51 to 0.21) | −0.82 (0.414) |
| AIMS2-SF: social week 32 (0–10) | 5.79 (5.44 to 6.14) | 5.67 (5.34 to 6.00) | −0.12 (−0.61 to 0.38) | −0.47 (0.638) |
| AIMS2-SF: work†—week 16 (0–10) | 3.47 (2.90 to 4.04) | 2.70 (2.12 to 3.28) | −0.77 (−2.28 to 0.74) | −1.02 (0.311) |
| AIMS2-SF: work†—week 32 (0–10) | 2.44 (1.99 to 2.89) | 2.71 (2.25 to 3.17) | 0.27 (−2.09 to 2.64) | 0.24 (0.810) |
AIMS2-SF, short form of arthritis impact measurement scale; ASES, Arthritis Self Efficacy Scale; ENAT, Educational Needs Assessment Tool.
*Bonferroni-adjusted p value=0.025 for significance at the α level.
†All missing data imputed except for AIMS2-SF: work where scores are only available for the patients who were working, week 16 and week 32 usual care N=26, intervention N=33.